N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-5-methoxy-2,3-dihydro-1,4-benzodioxine-7-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-5-methoxy-2,3-dihydro-1,4-benzodioxine-7-carboxamide
• 化学式: C₁₈H₂₀N₂O₅
• 分子量: 344.4
• InChiKey: KMBHNILDGJPMCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  85.9
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] COMBINATION THERAPY OF A T CELL THERAPY AND AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) INHIBITOR AND RELATED METHODS<br/>[FR] POLYTHÉRAPIE BASÉE SUR UNE THÉRAPIE PAR LYMPHOCYTES T ET UN INHIBITEUR DE PROTÉINE-2 HOMOLOGUE DE L'ACTIVATEUR DE ZESTE (EZH2) ET PROCÉDÉS ASSOCIÉS
  申请人：JUNO THERAPEUTICS INC

  公开号：WO2021035194A1

  公开（公告）日：2021-02-25

  Provided are methods, uses, and articles of manufacture of combination therapies involving immunotherapies and cell therapies, such as adoptive cell therapy, e.g. a T cell therapy, and the use of an inhibitor of an enhancer of zeste homolog 2 (EZH2), for treating subjects having or suspected of having a cancer, and related methods, uses, and articles of manufacture. The T cell therapy includes cells that express recombinant receptors such as chimeric antigen receptors (CARs).